10-Q: Regenerex Pharma Reports Q3 2024 Results: Net Loss Decreases Amid Focus on Wound Care Product Development

Regenerex Pharma's Q3 2024 filing reveals a decreased net loss compared to the previous year, as the company continues to develop and market wound care products.

Summary

• Regenerex Pharma, Inc. filed its Form 10-Q for the quarterly period ended December 31, 2024.
• The company is focused on developing and marketing wound care healing products.
• The net loss for the nine months ended December 31, 2024, was $1,116,656, compared to $3,251,000 for the same period in 2023.
• The decrease in net loss is attributed to reduced research and development expenses, lower stock-based compensation, and decreased administrative expenses, partially offset by increased payroll and interest expenses.
• The company has a lack of revenue history and a limited history of operations.
• Management plans to actively seek capital to enable the company to add new products and/or services to ultimately achieve profitability.
• The company's primary sources of liquidity and capital resources have been notes payable, which are not sufficient prospectively.
• The company's management concluded that the company did not maintain effective internal control over financial reporting as of December 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the net loss has decreased, the company faces significant financial challenges, including a large accumulated deficit, lack of revenue, and going concern uncertainties. The company is actively pursuing strategic initiatives, but their success is not guaranteed.

Positives

• The net loss decreased significantly compared to the previous year, indicating improved cost management.
• The company is actively pursuing strategic partnerships and distribution agreements to expand its market reach.
• The company is developing managed care agreements with southeastern states to manage their Medicaid wound care patients.
• The company is planning to launch its sales initiative during the fourth quarter of the year ending March 31, 2025.

Negatives

• The company has a significant accumulated deficit of $6,732,506 as of December 31, 2024.
• The company has excess liabilities over assets of $5,053,714 as of December 31, 2024.
• The company has a limited operating history and has not generated revenue.
• The company's management concluded that the company did not maintain effective internal control over financial reporting as of December 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company faces substantial known and unknown risks and uncertainties, including the impacts of COVID-19 or other future pandemics.
• The company's success depends on its ability to develop and market its wound care products effectively.
• The company's primary sources of liquidity and capital resources have been notes payable, which are not sufficient prospectively.
• The company may need to curtail or alter its plan of operations, seek additional capital on less favorable terms, and/or pursue other remedial measures if it is unable to raise additional capital.

Future Outlook

Management plans to actively seek capital to enable the company to add new products and/or services to ultimately achieve profitability, but there is no assurance that they can raise sufficient capital.

Management Comments

• Management is engaged in developing managed care agreements with southeastern states to manage their Medicaid wound care patients.
• Regenerex would provide our wound care products and protocols which would result in a large savings for the state Medicaid population.
• The Company is also in the process of negotiating with several distributors in various Middle Eastern countries to provide the Company's products.

Industry Context

The company operates in the wound care market, which is experiencing growth due to the increasing number of Americans with diabetes and obesity, as well as the aging population. The Affordable Healthcare Act (AHA) is changing how the entire wound care system is reimbursed in the US.

Comparison to Industry Standards

• The document states that Regenerex System has been shown in many clinical trials to successfully close up to 95% of non-responding chronic wounds within 90 days.
• The wounds clinically tested had already been subject to current protocols of treatment and failed to heal.
• The document claims that competitive clinical trials indicated there isn't another System that has the ability to close chronic wounds at these levels and speed.
• The document claims that QBx technology is the most efficacious, and clinically proven Chronic wound Care product in the world.

Management Changes

Legal Proceedings

• As of December 31, 2024, the Company is not involved in any material litigation.

Related Party Transactions

• The Company purchased assets from the Company's current Chief Executive Officer (CEO) and the former Secretary/Treasurer.
• The Company has entered into an agreement with Woundcare Labs, LLC., a party related to the CEO and the former CFO of the Company, to lease a plant and to lease equipment in Tennessee.
• During the nine-month periods ended December 31, 2024 and 2023, the Company's Chief Executive Officer (CEO) and the Company's former Chief Financial Officer (CFO) advanced the Company monies for operating expenses in the net amount of $ 6,157 and $ 4,557 , respectively.
• During the nine-month periods ended December 31, 2024 and 2023, the Company's CEO and former CFO advanced the Company monies for operating expenses in the amount of $284,460 and $105,000, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial condition and going concern uncertainties.
• Employees' job security is uncertain due to the company's financial instability.
• Customers may be affected by the company's ability to deliver its products and services.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to launch its sales initiative during the fourth quarter of the year ending March 31, 2025.
• The company will continue to seek guidance from third-party experts and consultants to gain a thorough understanding of complex and non-routine transactions.
• The company's management will continue to monitor and evaluate the designation, implementation and effectiveness of our internal controls and procedures and our internal controls over financial reporting on an ongoing basis and is committed to taking further action and implement additional enhancements or improvements, as necessary.

Key Dates

Keywords

wound care, Regenerex Pharma, financial results, intellectual property, net loss, Medicaid, capital raise, operating expenses, notes payable, going concern